Notícias e Atividades da Clearside Biomedical
Presença
Clearside Biomedical é uma empresa listada sob o símbolo CLSD (US).
Executivos
Veja o organograma con seus 18 executivos principais
Biografias mais buscadas da Clearside Biomedical
- George Lasezkay, Chief Executive Officer and Director
- William Humphries, Director
- Clay Thorp, Director
Recentes movimentos de executivos em Clearside Biomedical
- Anthony Gibney antes Director, foi promovido a Chairman of the Board (Notícia publicada em 5 de novembro de 2024).
Criar um alerta
para seguir os movimentos de executivos da Clearside Biomedical.
Biotecnologia
Clearside Biomedical possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).
Popular M&A news in Biotecnologia
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Clearside Biomedical
- Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore | Clearside Biomedical, Inc.- IR Site
- View more press releases Close
Redes sociais sobre Clearside Biomedical
- Clearside Biomedical na Wikipedia, Google News e Yahoo Finance
- Clearside Biomedical na LinkedIn, Twitter e YouTube
